EKSO BIONICS HOLDINGS, INC. — fact timeline

Andrew Schaap was appointed as Director at EKSO BIONICS HOLDINGS, INC..

“On June 29, 2026, Mr. Schaap was appointed to serve on the Board.”

Andrew Cordell Schaap was appointed as Director at EKSO BIONICS HOLDINGS, INC..

“On June 29, 2026, the board of directors (the “Board”) of ChronoScale Corporation, a Nevada corporation (the “Company”), increased the size of the Board from seven to eight members and appointed Mr. Andrew Cordell Schaap to serve as a member of the Board to fill the resulting vacancy, effective as of June 29, 2026.”

EKSO BIONICS HOLDINGS, INC. issued common stock.

“The A&R Articles increased the number of authorized shares of Common Stock from 141,428,571 shares to 290,000,000 shares, while maintaining the par value of $0.001 per share.”

EKSO BIONICS HOLDINGS, INC. issued 1,311,407 shares of Common Stock of common stock to Applied Parent for $12.01 per share.

“Parent 1,311,407 shares of Common Stock (the “Private Placement Shares”). The Private Placement Shares were sold in the APLD Parent PIPE Investment at an offering price of $12.01 per share, the closing price of the Common Stock on April 30, 2026, the date immediately preceding the date of execution of the Securities Purchase Agreement, for gross proceeds”

EKSO BIONICS HOLDINGS, INC.: Changed fiscal year end from December 31 to May 31.

“In connection with the Business Combination, as of the Closing Date, the Company changed its fiscal year end from December 31 to May 31.”

EKSO BIONICS HOLDINGS, INC.: Second Amended and Restated Bylaws adopted effective upon Closing on May 5, 2026 (effective 2026-05-05).

“Upon Closing and effective upon Closing, the Company adopted the Second Amended and Restated Bylaws (the “A&R Bylaws” and, together with the A&R Articles, the “Amended Charter Documents”).”

EKSO BIONICS HOLDINGS, INC.: Second Amended and Restated Articles of Incorporation filed with Nevada Secretary of State, effective May 5, 2026, including name change to ChronoScale Corporation, increase in authorized common shares from 141,428,571 to 290,000,000, and other changes (effective 2026-05-05).

“on May 1, 2026, the Company filed the Second Amended and Restated Articles of Incorporation (the “A&R Articles”) with the Secretary of State of the State of Nevada with a delayed effective date and time of 3:00 a.m. (Eastern Time) on May 5, 2026.”

EKSO BIONICS HOLDINGS, INC. underwent a change of control involving Applied Digital Corporation (closed 2026-05-05).

“On May 5, 2026 (the “Closing Date”), Ekso Bionics Holdings, Inc., a Nevada corporation (“Ekso” or the “Company”), consummated the previously announced business combination transaction (the “Business Combination”) contemplated by that certain Contribution and Exchange Agreement”

Richard Nottenburg was appointed as Director at EKSO BIONICS HOLDINGS, INC..

“the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg”

Douglas Miller was appointed as Director at EKSO BIONICS HOLDINGS, INC..

“the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg”

Scott G. Davis was appointed as Director at EKSO BIONICS HOLDINGS, INC..

“the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg”

William M. Clancy was appointed as Director at EKSO BIONICS HOLDINGS, INC..

“the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg”

Ying Cenly Chen was appointed as Director at EKSO BIONICS HOLDINGS, INC..

“the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg”

Ella Benson was appointed as Director at EKSO BIONICS HOLDINGS, INC..

“the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg”

Wes Cummins was appointed as Chairman of the Board at EKSO BIONICS HOLDINGS, INC..

“the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg”

Deborah Lafer Scher resigned as Director at EKSO BIONICS HOLDINGS, INC..

“the following directors tendered their resignations from the Board and each committee of the Board on which each such director respectively served: Mary Ann Cloyd, Corinna Lathan, Ph.D., Charles Li, Ph.D., and Deborah Lafer Scher”

Charles Li resigned as Director at EKSO BIONICS HOLDINGS, INC..

“the following directors tendered their resignations from the Board and each committee of the Board on which each such director respectively served: Mary Ann Cloyd, Corinna Lathan, Ph.D., Charles Li, Ph.D., and Deborah Lafer Scher”

Corinna Lathan resigned as Director at EKSO BIONICS HOLDINGS, INC..

“the following directors tendered their resignations from the Board and each committee of the Board on which each such director respectively served: Mary Ann Cloyd, Corinna Lathan, Ph.D., Charles Li, Ph.D., and Deborah Lafer Scher”

Mary Ann Cloyd resigned as Director at EKSO BIONICS HOLDINGS, INC..

“the following directors tendered their resignations from the Board and each committee of the Board on which each such director respectively served: Mary Ann Cloyd, Corinna Lathan, Ph.D., Charles Li, Ph.D., and Deborah Lafer Scher”

EKSO BIONICS HOLDINGS, INC. engaged CBIZ CPAs P.C. as its auditor.

“ay 5, 2026, the audit committee of the Board approved (i) the termination of the engagement of WithumSmith+Brown, PC (“Withum”), the Company’s independent registered public accounting firm prior to the Business Combination, and (ii) the engagement of CBIZ”

EKSO BIONICS HOLDINGS, INC. dismissed WithumSmith+Brown, PC as its auditor.

“On May 5, 2026, the audit committee of the Board approved (i) the termination of the engagement of WithumSmith+Brown, PC”

EKSO BIONICS HOLDINGS, INC. issued 1,311,407 shares of common stock to Applied Parent for $12.01 per share.

“APLD Parent PIPE Investment In connection with, and as a condition to Closing, on May 1, 2026, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Applied Parent (the “APLD Parent PIPE Investment”), pursuant to which the Company agreed to sell and issue to Applied Parent 1,311,407 shares of Common Stock (the “Private Placement Shares”). The Private Placement Shares will be sold in the APLD Parent PIPE Investment at an offering price of $12.01 per share, the closing price of the Common Stock on April 30, 2026, the date immediately preceding the date of execution of the Securities Purchase Agreement, for gross proceeds of approximately $15.75 million.”

EKSO BIONICS HOLDINGS, INC. entered into Securities Purchase Agreement with Applied Parent valued at gross proceeds of approximately $15.75 million (effective 2026-05-01).

“the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Applied Parent (the “APLD Parent PIPE Investment”), pursuant to which the Company agreed to sell and issue to Applied Parent 1,311,407 shares of Common Stock (the “Private Placement Shares”).”

EKSO BIONICS HOLDINGS, INC. issued 138,216,820 newly issued shares of common stock to Contributor.

“The Exchanged Shares will be issued in a private placement transaction in reliance on the exemption from the registration requirements provided by Rule 506(b) under Regulation D promulgated under the Securities Act.”

EKSO BIONICS HOLDINGS, INC.: Second Restated Bylaws introduce new provisions effective upon Closing, including quorum requirements, written consent rules, board quorum, amendment provisions, and no cumulative voting (effective 2026-02-14).

“On February 14, 2026, the Board approved the Second Restated Articles, which will only become effective immediately prior to the Closing, subject to stockholder approval, and the Second Amended and Restated Bylaws (the “Second Restated Bylaws”), which will only become effective upon the Closing.”

EKSO BIONICS HOLDINGS, INC.: Board approved Second Restated Articles, effective upon Closing, increasing authorized common shares from 141,428,571 to 290,000,000 and making other changes (effective 2026-02-14).

“On February 14, 2026, the Board approved the Second Restated Articles, which will only become effective immediately prior to the Closing, subject to stockholder approval, and the Second Amended and Restated Bylaws (the “Second Restated Bylaws”), which will only become effective upon the Closing.”

EKSO BIONICS HOLDINGS, INC.: Amendment No. 1 to Bylaws removes prohibition on stockholder action by written consent and revises record date provision to clarify applicability to meetings only (effective 2026-02-14).

“On February 14, 2026, the Board adopted an amendment (“Amendment No. 1”) to the Company’s amended and restated by-laws (the “Bylaws”) to align certain provisions of the Bylaws with Nevada law by (i) removing the provision of the Bylaws prohibiting stockholder action by written consent, and (ii) revising the record date provision to clarify that such provision is only applicable to meetings of stockholders.”

EKSO BIONICS HOLDINGS, INC. entered into Contribution and Exchange Agreement with APLD Intermediate HoldCo LLC, APLD ChronoScale HoldCo LLC, and Applied Digital Cloud Corporation (effective 2026-02-15).

“On February 15, 2026, Ekso Bionics Holdings, Inc., a Nevada corporation (“Ekso” or the “Company”), entered into a Contribution and Exchange Agreement (the “Contribution and Exchange Agreement”) with APLD Intermediate HoldCo LLC, a Delaware limited liability company (“APLD Intermediate”), APLD ChronoScale HoldCo LLC, a Delaware limited liability company and a wholly owned subsidiary of APLD Intermediate (“Contributor”), each a wholly owned direct or indirect subsidiary of Applied Digital Corporation, a Nevada corporation (“APLD”), and Applied Digital Cloud Corporation, a Nevada corporation, which at the time of the Closing (as defined below), will be a wholly owned subsidiary of Contributor (“Cloud”)”

EKSO BIONICS HOLDINGS, INC. issued up to an aggregate of 355,960 shares of Common Stock of warrant to certain institutional and accredited investors for exercise price of $8.22 per share.

“warrants (the “Warrants”) to purchase up to an aggregate of 355,960 shares of Common Stock at an exercise price of $8.22 per share of Common Stock”

EKSO BIONICS HOLDINGS, INC. issued 5,852 shares of the Company's newly designated Series B Convertible Preferred Stock of preferred stock to certain institutional and accredited investors for stated value of $1,000 per share.

“On January 20, 2026, Ekso Bionics Holdings, Inc. (the “Company”) entered into securities purchase agreements (collectively, the “Purchase Agreements”) with certain institutional and accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”), (i) an aggregate of 5,852 shares of the Company’s newly designated Series B Convertible Preferred Stock, with a par value $0.001 per share and stated value (the “Stated Value”) of $1,000 per share (the “Series B Preferred Stock”)”

EKSO BIONICS HOLDINGS, INC.: Filed a Certificate of Designation for Series B Convertible Preferred Stock to the Restated Articles of Incorporation (effective 2026-01-22).

“In connection with the Private Placement, on January 22, 2026, the Company filed a Certificate of Designation of the Powers, Preferences and Relative, Participating, Option and Other Restrictions of the Series B Preferred Stock (the “Certificate of Designation”) to the Company’s Restated Articles of Incorporation with the Secretary of State of the State of Nevada.”

EKSO BIONICS HOLDINGS, INC. entered into Purchase Agreements with certain institutional and accredited investors valued at approximately $5.3 million (effective 2026-01-20).

“On January 20, 2026, Ekso Bionics Holdings, Inc. (the “Company”) entered into securities purchase agreements (collectively, the “Purchase Agreements”) with certain institutional and accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”), (i) an aggregate of 5,852 shares of the Company’s newly designated Series B Convertible Preferred Stock, with a par value $0.001 per share and stated value (the “Stated Value”) of $1,000 per share (the “Series B Preferred Stock”) convertible into an aggregate of 711,922 shares (the “Conversion Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”) at a conversion price of $8.22 per share, subject to certain customary adjustments, and (ii) warrants (the “Warrants”) to purchase up to an aggregate of 355,960 shares of Common Stock at an exercise price of $8.22 per share of Common Stock.”

EKSO BIONICS HOLDINGS, INC. incurred term loan of $2.0 million with B. Riley Commercial Capital, LLC at 10.0% per annum maturing the earlier of the receipt of $2.4 million in net proceeds from the sale of the equity interests of the Company from new equity investors (a “Qualified Financin.

“On September 12, 2025, Ekso Bionics Holdings, Inc. (the “Company”) entered into a Secured Promissory Note and Security Agreement (the “Agreement”), by and among the Company, Ekso Bionics, Inc., a Delaware corporation and subsidiary of the Company (the “Subsidiary”), as guarantor, and B. Riley Commercial Capital, LLC, as lender (the “Lender”). The Agreement provides for a secured term loan in an aggregate principal amount of up to $2.0 million.”

EKSO BIONICS HOLDINGS, INC. reported three months ended March 31, 2024 results: revenue $3.8 million, net income $3.4 million, EPS $0.20 per basic and diluted share.

“● Received final payment determination for Medicare reimbursement from the Centers for Medicare & Medicaid Services (“CMS”) for Ekso Indego Personal ● Reported revenues of $3.8 million for the first quarter of 2024 ● Achieved gross margin of 52% for the quarter ended March 31, 2024 ● Sold a total of 29 EksoHealth units in the first quarter of 2024 “We started”

EKSO BIONICS HOLDINGS, INC. reported financial results for three and twelve months ended December 31, 2023.

“On March 4, 2024 Ekso Bionics Holdings, Inc. (the “Company”) reported its financial results for the three and twelve months ended December 31, 2023. The full text of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”

EKSO BIONICS HOLDINGS, INC. reported the fiscal year ended December 31, 2023 results: revenue in the range of $18.1 million to $18.3 million.

“Total revenue for fiscal year 2023 is estimated to be in the range of $18.1 million to $18.3 million”

EKSO BIONICS HOLDINGS, INC. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue in the range of $4.7 million to $4.9 million.

“Total revenue for the fourth quarter of 2023 is estimated to be in the range of $4.7 million to $4.9 million”

EKSO BIONICS HOLDINGS, INC. reported financial results for the three and nine months ended September 30, 2023.

“On October 26, 2023 Ekso Bionics Holdings, Inc. (the “Company”) reported its financial results for the three and nine months ended September 30, 2023.”

EKSO BIONICS HOLDINGS, INC. amended term loan with Pacific Western Bank at the greater of (A) the Lender's "prime rate" then in effect and (B) 4.50% maturing August 13, 2026.

“The Amendment amends that certain Loan and Security Agreement dated as of August 13, 2020, by and between the Borrower and the Lender to, among other things, (i) have daily borrowings under the Term Loan bear interest at a variable annual rate equal to the greater of (A) the Lender's "prime rate" then in effect and (B) 4.50%, (ii) cause the Borrower to maintain all of its depository, operating, and investment accounts with Lender and (iii) extend the Term Loan Maturity Date to August 13, 2026.”

EKSO BIONICS HOLDINGS, INC. amended Fifth Amendment to Loan and Security Agreement with Pacific Western Bank (effective 2023-08-17).

“On August 17, 2023, Ekso Bionics Holdings, Inc. (the “Company”), Ekso Bionics, Inc., the Company’s wholly owned subsidiary (“Ekso Bionics” and, together with the Company, the “Borrower”) and Pacific Western Bank (the “Lender”), entered into the Fifth Amendment to Loan and Security Agreement (the “Amendment”).”

EKSO BIONICS HOLDINGS, INC. reported the six months ended June 30, 2023 results: revenue $8.8 million, net income $8.6 million, EPS $0.64 per basic and diluted share.

“Revenue was $8.8 million for the six months ended June 30, 2023, an increase of 46%, compared to $6.0 million for the same period in 2022. The Company booked a total of 67 EksoHealth devices in the first half of 2023. Gross profit for the six months ended June 30, 2023 was $4.3 million, representing a gross margin of approximately 48%, compared to gross profit of $2.9 million for the same period in 2022, representing a gross margin of 47%. The overall increase in gross margin was primarily due to lower device costs. Sales and marketing expenses for the six months ended June 30, 2023 were $4.4 million, compared to $3.5 million the same period in 2022. The increase was primarily due to higher compensation costs associated with the acquisition of HMC, an increase in marketing activities, and severance expense. Research and development expenses for the six months ended June 30, 2023 were $2.6 million, compared to $1.8 million for the same period in 2022. The increase was primarily due to h”

EKSO BIONICS HOLDINGS, INC. reported the quarter ended June 30, 2023 results: revenue $4.7 million, net income $4.2 million, EPS $0.31 per basic and diluted share.

“Revenue was $4.7 million for the quarter ended June 30, 2023, an increase of 36%, compared to $3.5 million for the same period in 2022. The Company booked a total of 44 EksoHealth devices in the second quarter of 2023. Gross profit for the quarter ended June 30, 2023 was $2.3 million, an increase of 37% from the same period in 2022, representing a gross margin of approximately 48% in the second quarter of 2023, compared to a gross margin of 47% for the same period in 2022. The increase in gross margin was primarily due to lower device costs. Sales and marketing expenses for the quarter ended June 30, 2023 were $2.3 million, compared to $1.8 million for the same period of 2022. The increase was primarily due to higher compensation costs associated with the acquisition of the Human Motion Control (“HMC”) business unit, severance expense and an increase in marketing activities. Research and development expenses for the quarter ended June 30, 2023 were $1.4 million, compared to $0.9 millio”

EKSO BIONICS HOLDINGS, INC. shareholders approved Ratification of appointment of WithumSmith+Brown, PC as independent auditors at the 2023-06-08 meeting.

“For Against Abstained Broker Non-votes 7,027,946 152,140 49,764 n/a”

EKSO BIONICS HOLDINGS, INC. shareholders approved Advisory vote on named executive officer compensation at the 2023-06-08 meeting.

“For Against Abstained Broker Non-votes 4,111,482 293,055 67,949 2,757,364”

EKSO BIONICS HOLDINGS, INC. shareholders approved Amendment of 2014 Equity Incentive Plan to increase authorized shares from 2,524,286 to 3,724,286 at the 2023-06-08 meeting.

“For Against Abstained Broker Non-votes 3,898,757 551,457 22,272 2,757,364”

EKSO BIONICS HOLDINGS, INC. shareholders approved Election of five persons to the Company’s board of directors at the 2023-06-08 meeting.

“Scott G. Davis 4,312,949 159,537 2,757,364”

EKSO BIONICS HOLDINGS, INC. amended Amendment with H.C. Wainwright & Co., LLC (effective 2023-06-12).

“On June 12, 2023, Ekso Bionics Holdings, Inc. (the “Company”) entered into an amendment (the “Amendment”) to that certain At the Market Offering Agreement dated as of October 9, 2020 (the “Sales Agreement”), by and between the Company and H.C. Wainwright & Co., LLC (the “Agent”), pursuant to which the Company may offer and sell, from time to time, through the Agent, shares of the Company’s common stock, par value $0.001 per share (the “Shares”), in an “at-the-market” offering.”

EKSO BIONICS HOLDINGS, INC. reported three months ended March 31, 2023 results: revenue $4.1 million, net income $4.4 million, EPS $0.33 per basic and diluted share.

“for medical and industrial use, today reported financial results for the three months ended March 31, 2023. Recent Highlights and Accomplishments • Achieved record revenues of $4.1 million in the first quarter of 2023, up 61% from the first quarter of 2022 • Delivered products across continuum of care following the addition of the Indego ® product line • Booked a”

EKSO BIONICS HOLDINGS, INC.: Amended and restated bylaws to address universal proxy rules and update provisions related to calling of stockholder and Board meetings (effective 2023-04-20).

“On April 20, 2023, the Board of the Company adopted amended and restated bylaws (the “Amended and Restated Bylaws”), which became effective immediately. Among other things, the Amended and Restated Bylaws address the universal proxy rules adopted by the U.S. Securities and Exchange Commission and update certain provisions related to the calling of stockholder and Board meetings.”

Stanley Stern resigned as director at EKSO BIONICS HOLDINGS, INC..

“On April 25, 2023, Stanley Stern, a member of the board of directors (the “Board”) of Ekso Bionics Holdings, Inc. (the “Company”), notified the Company of his resignation from the Board, effective on April 26, 2023.”